Table 1.
Primary cohort: Baseline characteristics in persons with incident stress related disorder diagnosis (exposed cohort) and matched controls (unexposed cohort).
| Demographics | Exposed cohort (n = 30,998) | Unexposed cohort (n = 116,677) |
|---|---|---|
| Age, yr (IQR) | 45 (35-56) | 46 (35-57) |
| Women, n (%) | 22,092 (71) | 81,068 (69) |
| Follow-up, yr (median, IQR) | 3.6 (2.2-4.9) | 3.1 (2.0-4.5) |
| eGFR, ml/min per 1.73 m2(IQR) | 100.5 (87.8-111.9) | 100.2 (87.1-112.0) |
| eGFR strata (ml/min/1.73m2) | ||
| eGFR ≥ 90, n (%) | 22,132 (71.4) | 82,346 (70.6） |
| eGFR:60-89, n (%) | 7859 (25.3) | 30,366 (26.0) |
| eGFR:30-59, n (%) | 927 (3.0) | 3658 (3.1) |
| eGFR < 30, n (%) | 80 (0.3) | 307 (0.3) |
| Type of stress related disorders, No. (%) | ||
| Posttraumatic stress disorder | 2033 (6.5) | |
| Acute stress reaction | 3476 (11.2) | |
| Adjustment disorder | 1782 (5.8) | |
| Other stress reaction | 23,707 (76.5) | |
| Psychiatric comorbidity | 8816 (28.4) | 13,020 (11.2) |
| History of other psychiatric disorders | ||
| History of severe somatic disease | 6921 (22.3) | 19,420 (16.6) |
| Hypertension, n (%) | 7981 (25.8) | 30,654 (26.3) |
| Diabetes Mellitus, n (%) | 1814 (5.9) | 8798 (7.5) |
| Myocardial infarction, n (%) | 623 (2.0) | 2791 (2.4) |
| Congestive heart failure, n (%) | 619 (2.0) | 3300 (2.8) |
| Peripheral vascular disease, n (%) | 389 (1.3) | 1821 (1.6) |
| Cerebrovascular disease, n (%) | 1064 (3.4) | 4350 (3.7) |
| Recent cancer (3 years), n (%) | 2003 (6.5) | 9696 (8.3) |
| Chronic obstructive pulmonary disease, n (%) | 2240 (7.2) | 8237 (7.1) |
| Rheumatic disease, n (%) | 541 (1.8) | 3444 (3.0) |
| Peptic ulcer disease, n (%) | 535 (1.7) | 2029 (1.7) |
| Medications | ||
| Aspirin/NSAIDs | 8498 (27.4) | 30,868 (26.5) |
| ACEi/ARBs | 3932 (12.7) | 16,239 (13.9) |
| Mineralocorticoid receptor antagonists | 320 (1.0) | 1667 (1.4) |
| Beta blockers | 4363 (14.1) | 15,399 (13.2) |
| Other Diuretics | 2360 (7.6) | 9742 (8.4) |
| Calcium channel blockers | 1838 (5.9) | 7549 (6.5) |
| Selective serotonin reuptake inhibitors | 6667 (21.5) | 10,879 (9.3) |
| Lithium | 1387 (4.5) | 3847 (3.3) |
ABRs, Angiotensin II receptor blockers; ACEi, Angiotensin-converting enzyme inhibitors; IQR, Interquartile range; NSAID, non-steroidal anti-inflammatory drugs.
Baseline eGFR is defined as the average of all measurements 1-12 months before index date. History of psychiatric disorders (other than stress related disorders) diagnosed from 3 months before to 1 year after the diagnosis of stress related disorders.